Contract Term: 2024 – 2028
TUM is participating in the nationwide DEAL agreement with Elsevier, negotiated on behalf of the Alliance of Science Organizations and the German Rectors' Conference. In addition to the Elsevier journal portfolio, the agreement also includes the brands Cell Press and The Lancet.
The following services are available through the TUM University Library:
- Reading Access
At TUM, you have electronic access to almost the entire journal portfolio of Elsevier, including titles from Cell Press and The Lancet. This includes reading rights for current issues and archival access to back volumes.
- Open Access Publishing
As the "Submitting Corresponding Author" affiliated with TUM, you have the opportunity to publish your papers Open Access in almost all journals from Elsevier, Cell Press and The Lancet. For articles accepted for publication from 01/01/2024 onwards, no publication fees incur for you personally. The costs for Open Access publishing are centrally covered by TUM and processed through the University Library. If you opt for additional services (e.g., for color illustrations or extra length) with the publisher, Elsevier will directly invoice you for those expenses.
Exempt from the Agreement
Some journals from learned societies and academic associations published by Elsevier are not covered by the DEAL agreement. Journal owners have not agreed to include their titles in the Publish & Read agreement, among those are journals such as "Blood" or "Blood Advances" from the American Society of Hematology.
Mandatory Affiliation Statement
For cost coverage and the precise attribution of your publication, it is crucial that you indicate TUM as your primary affiliation and utilize the binding, standardized affiliation designation. Please adhere to the specifications outlined in the TUM Publication Guidelines for all your publication projects.
Author instructions on the Elsevier website